In the population of patients with apocrine tumors, the association was close to significance, but the small number of patients made it impossible to draw robust conclusions ( n =21; MFS: p =0.06 and OS: p =0.07) ( Figure S3 ).
This finding is not consistent with Lehmann's results showing a pan-PI3K inhibitor and a dual PI3K/mTOR inhibitor to be more effective in LAR CDX than bicalutamide in two cell-line models: bicalutamide slowed growth at the limit of significance, but the PI3K inhibitor appeared to be more effective both alone and in combination with bicalutamide 13 , and several clinical trials of combination therapy for AR + TNBC are currently underway ( NCT02457910 , NCT03207529 ).